Archives: 2017 / 2016 / 2015



2012 Archives

Dec 17, 2012
New Assay Measures Testosterone Levels to Help Diagnose Related Conditions in Both Men and Women
Dec 13, 2012
Studies have found new diagnostic tests in development for heart conditions are expected to help clinicians reduce time to heart attack treatment and potentially improve the way heart attacks are diagnosed in women
Dec 7, 2012
Abbott Expects to Complete Separation of AbbVie on Jan. 1, 2013
Nov 27, 2012
-- HUMIRA is the First Biologic Approved in the European Union for the Treatment of Pediatric Crohn's, Offering At-Home Administration
Nov 13, 2012
- Interferon-free Hepatitis C Regimens will be Studied in Broad Patient Populations across Multiple Countries
Nov 12, 2012
- Reduction of disease activity, prevention of further joint damage and preservation of physical function were the three goals evaluated
Nov 12, 2012
-In the Phase 3 ABILITY-1 trial, HUMIRA patients experienced a statistically significant improvement in select measures of physical function and health-related quality of life (HRQOL) at 12 weeks
Nov 10, 2012
- Investigational Triple-DAA Regimen plus Ribavirin Treatment for 12 Weeks Demonstrated High SVR12 Rates in Intent-to-Treat Analysis
Oct 30, 2012
Ensure Complete combines muscle, heart, immune system and bone benefits in one simple shake to help adults complement their diet and achieve health goals.
Oct 19, 2012
- Positive Opinion Based on Supporting Data from HUMIRA Study in Pediatric Patients with Severely Active Crohn's Disease
Oct 17, 2012
- Third-Quarter Ongoing EPS of $1.30 (GAAP EPS of $1.21), an Increase of 10.2 Percent and Exceeding the Company's Quarterly Guidance Range -
Oct 12, 2012
More than 20,000 Public Votes Helped Determine this Year's Undergraduate and Graduate Scholarship Recipients
Sep 28, 2012
- HUMIRA is now indicated to treat adult patients with moderate to severe ulcerative colitis who have had an inadequate response to immunosuppressants